Jon Napitupulu

Iovance Biotherapeutics has granted inducement stock options covering 164,900 shares to 11 new non-executive employees, effective November 20, 2025....

Inventiva has extended its cash runway into late Q1 2027 after completing a U.S. public offering in November that...

Hanmi Pharmaceutical will take Aptose Biosciences private, acquiring all remaining shares it does not already own for C$2.41 per...

Valneva reported nine-month 2025 revenues of €127 million, up 9% year over year, alongside a sharp reduction in operating...

BioSyent reported a strong third quarter, with net revenues up 28% to CAD 12.2 million and EBITDA up 27%...

Profusa has completed its reverse recapitalization with NorthView Acquisition Corporation, cut net debt to approximately $14 million as of...

Novartis has rolled forward its mid-term outlook, guiding to a 5–6% constant-currency sales CAGR for 2025–2030 and lifting peak...

Valneva reported nine-month 2025 revenues of €127.0 million, up 8.9% year over year, with product sales rising 6.2% to...

Protext Mobility has issued a broad corporate update: IFRS-audited 2022 and 2023 financials are complete, 2024 filings are underway...

Tempest Therapeutics is acquiring Factor Bioscience’s dual‑targeting CAR‑T programs in an all‑stock deal that will hand an affiliate of...